From Nasdaq: 2025-05-31 09:55:00

Regeneron Pharmaceuticals Inc. announced positive results from the Phase 3 C-POST trial, showing that PD-1 inhibitor Libtayo is effective in treating high-risk cutaneous squamous cell carcinoma post-surgery. The trial demonstrated a 68% reduction in the risk of disease recurrence or death, along with significant reductions in locoregional and distant recurrence rates. The data suggests that cemiplimab is a highly active therapy for this type of cancer, with promising outcomes across primary and secondary endpoints. This news provides hope for patients with this aggressive form of skin cancer.



Read more at Nasdaq: Regeneron Unveils Detailed Phase 3 C-POST Trial Results For Libtayo In High-Risk CSCC Patients